Top Markets
Coin of the day
Norris Medicines Limited Norris Medicines Limited

Norris Medicines Limited

NORRIS
Rank in Stocks #37398
Norris Medicines Ltd. focuses on the development and production of... Norris Medicines Ltd. focuses on the development and production of pharmaceutical compounds, medicinal chemicals, and botanical extracts. Their diverse product range addresses various health concerns, encompassing categories like antibiotics, anti-inflammatory agents, anti-emetics, nutritional supplements, cough and cold remedies, dermatological and allergy treatments, anti-malarial drugs, and medications for diabetic and cardiac conditions. The company, which established its operations in 1990, is based in Ankleshwar, India.
Share Price
$0.17547045
Last synced: 2026-08-14
Market Cap
$1.75M
Change (1 day)
-2.51%
Change (1 year)
-10.85%
Country
IN
Trade Norris Medicines Limited (NORRIS)

Category

P/E ratio for Norris Medicines Limited (NORRIS)
P/E ratio as of 2026 TTM: 0
According to Norris Medicines Limited latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Norris Medicines Limited from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.